The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 10, 2024
Filed:
Feb. 27, 2018
Juno Therapeutics, Inc., Seattle, WA (US);
Brian Christin, Seattle, WA (US);
Michael Gerard Covington, Seattle, WA (US);
Kedar Himanshu Dave, Seattle, WA (US);
Richard James Getto, Jr., Seattle, WA (US);
Tom Kowski, Seattle, WA (US);
Ryan P. Larson, Seattle, WA (US);
Christopher Glen Ramsborg, Seattle, WA (US);
Nikolaus Sebastian Trede, Seattle, WA (US);
Clinton Weber, Seattle, WA (US);
James Boyd Whitmore, Seattle, WA (US);
Nathan Yee, Seattle, WA (US);
Pascal Beauchesne, Seattle, WA (US);
Travis Beckett, Seattle, WA (US);
Samuel Charles Blackman, Seattle, WA (US);
Nathaniel Chartrand, Seattle, WA (US);
Mel Davis-Pickett, Seattle, WA (US);
Mark Gilbert, Seattle, WA (US);
Nathaniel Lambert, Seattle, WA (US);
He Li, Seattle, WA (US);
Mary Mallaney, Seattle, WA (US);
Kathryn Lindsay Pollock, Seattle, WA (US);
Valerie Odegard, Seattle, WA (US);
Jeff Smith, Seattle, WA (US);
Claire Sutherland, Seattle, WA (US);
Andrew W. Walker, Seattle, WA (US);
Juno Therapeutics, Inc., Seattle, WA (US);
Abstract
Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.